Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer.

作者信息

Price Nancy

出版信息

Clin Prostate Cancer. 2004 Sep;3(2):77-9. doi: 10.1016/s1540-0352(11)70065-8.

DOI:10.1016/s1540-0352(11)70065-8

PMID:15479488

Abstract

摘要

相似文献

Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer.

Clin Prostate Cancer. 2004 Sep;3(2):77-9. doi: 10.1016/s1540-0352(11)70065-8.

Annual zoledronic acid: is less more?

J Clin Oncol. 2007 Mar 20;25(9):1026. doi: 10.1200/JCO.2006.08.8146.

Activity of epothilone B analogues ixabepilone and patupilone in hormone-refractory prostate cancer.

Clin Prostate Cancer. 2004 Sep;3(2):80-2. doi: 10.1016/s1540-0352(11)70066-x.

Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.

Breast. 2003 Aug;12 Suppl 2:S22-9. doi: 10.1016/s0960-9776(03)80160-1.

Bisphosphonates in prostate cancer: where are we and where should we go?

J Natl Cancer Inst. 2003 Sep 3;95(17):1262-3. doi: 10.1093/jnci/djg062.

Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.

J Natl Cancer Inst. 2003 Sep 3;95(17):1273-4. doi: 10.1093/jnci/95.17.1273.

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.

Urology. 2005 Jan;65(1):126-30. doi: 10.1016/j.urology.2004.08.041.

Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.

Urol Int. 2008;80(4):448-50. doi: 10.1159/000132707. Epub 2008 Jun 27.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.

Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.

Breast. 2003 Aug;12 Suppl 2:S37-44. doi: 10.1016/s0960-9776(03)80162-5.

引用本文的文献

Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.

BMC Cancer. 2006 Jan 17;6:15. doi: 10.1186/1471-2407-6-15.

Prostate cancer in the elderly.

Int Urol Nephrol. 2005;37(4):797-806. doi: 10.1007/s11255-005-0402-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验